Maat Pharma Stock Quote MAAT - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

7.20

Bid

7.18

Ask

7.26

Volume

2,454

7.20 Day's Range 7.42

6.52 52 Week Range 9.96

Market Cap

83.637M

Previous Close

7.36

Open

7.38

Last Trade

7.2

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

6,196

Shares Outstanding

11,616,199

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

2.23M

Net Profit

-19.72M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.maatpharma.com

Headquarters

Lyon, Rhone, Fra

Founded

Maat Pharma SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker MAAT. The last closing price for Maat Pharma was 7.36 €. Over the last year, Maat Pharma shares have traded in a share price range of 6.52 € to 9.96 €.

Maat Pharma currently has 11,616,199 shares outstanding. The market capitalization of Maat Pharma is 85.50 € million.

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good...

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

L'étude a atteint son critère principal d’évaluation avec un taux de réponse globale gastro-intestinale significatif au 28ème jour de 62...

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma...

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD...

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.32	-4.25531914894	7.52	7.72	7.2	2919	7.35927783	DE
4	-0.96	-11.7647058824	8.16	8.46	7.2	4959	7.75932269	DE
12	-0.78	-9.77443609023	7.98	9.96	7.2	6196	8.18878924	DE
26	-0.14	-1.90735694823	7.34	9.96	6.8	3693	8.03125804	DE
52	0.1	1.40845070423	7.1	9.96	6.52	2735	8.08366757	DE
156	-5.6	-43.75	12.8	13.55	4.5	1550	8.18254036	DE
260	-6.3	-46.6666666667	13.5	14.4	4.5	1685	8.99963104	DE

MAAT - Frequently Asked Questions (FAQ)

What is the current Maat Pharma share price?

The current share price of Maat Pharma is 7.20 €

How many Maat Pharma shares are in issue?

Maat Pharma has 11,616,199 shares in issue

What is the market cap of Maat Pharma?

The market capitalisation of Maat Pharma is EUR 85.5M

What is the 1 year trading range for Maat Pharma share price?

Maat Pharma has traded in the range of 6.52 € to 9.96 € during the past year

What is the reporting currency for Maat Pharma?

Maat Pharma reports financial results in EUR

What is the latest annual turnover for Maat Pharma?

The latest annual turnover of Maat Pharma is EUR 2.23M

What is the latest annual profit for Maat Pharma?

The latest annual profit of Maat Pharma is EUR -19.72M

What is the registered address of Maat Pharma?

The registered address for Maat Pharma is 70 AVENUE TONY GARNIER, LYON, RHONE, 69007

What is the Maat Pharma website address?

The website address for Maat Pharma is www.maatpharma.com

Which industry sector does Maat Pharma operate in?

Maat Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALADOAdomos	0.57 € (284,900.00%)	31.49k
MLSMLSmalto	0.02 € (42.86%)	25.39k
ALCABCabasse SA	1.94 € (22.78%)	43.16k
YOUNIYounited Financial SA	13.00 € (18.18%)	146
VACBSPierre & Vacances	0.064 € (16.36%)	24.78k
ALCYBCybergun	0.0001 € (-50.00%)	106.7M
ALBOOBOOSTHEAT	0.0122 € (-25.61%)	929.3k
BAIOdyssey Acquisition SA	0.21 € (-25.27%)	986.4k
ETLEutelsat Communications	1.39 € (-19.14%)	3.55M
ALOPMOncodesign Precision Medicine SA	0.42 € (-14.29%)	72.51k
ATOAtos SE	0.0027 € (8.00%)	954.9M
ALVERVergnet	0.0006 € (0.00%)	265.64M
BCPBanco Comercial Portugues SA	0.5324 € (3.70%)	144.83M
ALCYBCybergun	0.0001 € (-50.00%)	106.7M
ALHPIHopium SA	0.0025 € (-3.85%)	17.14M

zab 3 minutes ago

He'll no, Republicans enjoy destroying America, it's what they do, trump is just sad to look at. He appears in his makeup, looking like a corpse, even his hair piece varies so much that you wonder how bald he has become. His 325 lbs forces him to sit more, and even when he stands you know it will

Gmenfan 4 minutes ago

Certainly more than Biden provided:

North Carolina High School Students Create Tiny Homes for Hurricane Helene Victims
ELIZABETH WEIBEL 15 Feb 2025 2:50

High school students in North Carolina have created tiny homes in their carpentry class as part of an effort

Gmenfan 4 minutes ago

Kimbrown 4 minutes ago

Is CCSAB Glen?

FNMA

Gmenfan 6 minutes ago

Trump on DOGE: “We literally started off with >

14 or 15 young geniuses.
Now we have 100 young geniuses.
And what’s happened…
People are calling up from all over the country wanting to help Elon Musk.”
https://x.com/unusual_whales/status/1890778342401667235

Jetmek_03052 7 minutes ago

Last "shareholder update" was published Jan 17th. Considering the shrinking share price, it wouldn't be surprising to see another update this coming week. This needs another little "goose". Get on it Linda!

DBMM

chilar4567 9 minutes ago

Thx WOW, a great resource.
All we need now is a certain seller to get out of the way.

PAYS

Gmenfan 9 minutes ago

Hey Larry, Happy Birthday!

TJG 10 minutes ago

Love shares are issued as restricted for one year, but if the lender requests a earlier removal of the restriction, 6 months is the earliest, the company can allow it. When that happens the lender will most often give something in return. That is most often a reduction in the interest owed. It's not

AFFU

Disquisition 11 minutes ago

What are we MELTING DOWN about today, fellow Democrat loons?

Trump? Elon Musk? Tariffs? Stormy Daniels? Russia? Putin? A European army? Federal government programs being cut? Abortion? Pete Hegseth?

What is our Democrat media telling us that we need to endlessly obsess

zab 12 minutes ago

Trump wanted his supporters to murder Mike Pence, even Hillary Clinton, and it never bothered you. Besides you never really see trump anymore, President Musk and his 4 year old son are trumps real enemies.

SkeBallLarry 12 minutes ago

" Capgain ~ I appr. it soo-much " .. !!

SkeBallLarry 14 minutes ago

" I thank you, Bull ~ now inna short rows " .. !!

SkeBallLarry 15 minutes ago

" Tanks, K2 ~ Heey, didn't know >

Mr. Trump was coming ...

" He's everywhere ~ He's everywhere " .. !!

and thanks for the BD Wishes " .. !!

newmedman 16 minutes ago

yes, keep up without fear, before you know, all friends will be here.
alive or dead you served us well
come along and serve in my woke hell.
[yt]k9SB69gIKW8[/yt]

HenryB3 16 minutes ago

I see some have been drinking kool aide all weekend long. The carrot and dangling is a good analogy. Keep stringing along daydreamers and fantasy land folk to the "promise land" of $4,5,6 dollar buyout rumors. All while stock is being sold by a huge holder. Now a few are waking up, just not fast

ELTP

capgain 16 minutes ago

Happy Birthday, Larry. Have a great day!

Adagio Lector 18 minutes ago

You misspelled Yuge.

:)

FNMA

PENNIEStoSTACKS 19 minutes ago

B3 https://basement.fun

B3USD

bigtalan 21 minutes ago

The word is the conference went very well, they had very good meetings and a well received presentation , nothing moves fast from theses types of meetings. Hopefully we hear good news about the filings in the next week or two . GLTA

RSPI

Guzzi62 21 minutes ago

The peer reviewed journal should sustain much higher sp than we have now.

Institutions now own over 40% I read somewhere, so they decide on what the price is, guess they have been accumulating since the journal came out.

AVXL

brooklyn13 21 minutes ago

I'm pretty sure I don't care about how old you actually are, my point was that you sound like a child or someone participating in the click count economy. From New Delhi.

And speaking of DD, didn't you make up that whole thing about peoples' bank accounts being emptied? Let me guess

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Maat Pharma SA (MAAT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Maat Pharma SA

Ask ADVFN Intelligence (AI)

MAAT Latest News

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Maat Pharma SA (MAAT) Quote

Maat Pharma SA (MAAT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Maat Pharma SA

Ask ADVFN Intelligence (AI)

MAAT Latest News

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free